Earnings & Valuation
This table compares Endonovo Therapeutics and its rivals revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Endonovo Therapeutics | $170,000.00 | -$400,000.00 | N/A |
| Endonovo Therapeutics Competitors | $434.13 million | -$68.27 million | -10.42 |
Endonovo Therapeutics’ rivals have higher revenue, but lower earnings than Endonovo Therapeutics. Endonovo Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
Endonovo Therapeutics has a beta of 1.98, meaning that its share price is 98% more volatile than the S&P 500. Comparatively, Endonovo Therapeutics’ rivals have a beta of 11.28, meaning that their average share price is 1,028% more volatile than the S&P 500.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Endonovo Therapeutics | -6,075.54% | N/A | -279.35% |
| Endonovo Therapeutics Competitors | -2,626.20% | -359.54% | -43.35% |
Insider and Institutional Ownership
39.3% of shares of all “Pharmaceutical Preparations” companies are owned by institutional investors. 5.6% of Endonovo Therapeutics shares are owned by insiders. Comparatively, 14.1% of shares of all “Pharmaceutical Preparations” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Endonovo Therapeutics rivals beat Endonovo Therapeutics on 6 of the 9 factors compared.
Endonovo Therapeutics Company Profile
Endonovo Therapeutics, Inc. is a biotechnology company, which engages in the development of bio-electronic approach to regenerative medicine. The firm also develops, manufactures and distributes evolutionary medical devices focused on the healing of wounds and reduction of pain, edema and inflammation on and in the human body. Its technology and products include Electroceuticals, EFECT Trial, SofPulse, Electroceutical Therapy, and Scientific Studies. The company was founded in November 2008 and is headquartered in Woodland Hills, CA.
Receive News & Ratings for Endonovo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endonovo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
